|
1
|
DeSantis CE, Ma J, Goding Sauer A, Newman
LA and Jemal A: Breast cancer statistics, 2017 racial disparity in
mortality by state. CA Cancer J Clin. 67:439–448. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Global Burden of Disease Cancer
Collaboration; Fitzmaurice C, Allen C, Barber RM, Barregard L,
Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al:
Global, regional, and national cancer incidence, mortality, years
of life lost, years Lived with disability, and disability-adjusted
life-years for 32 cancer groups, 1990 to 2015: A systematic
analysis for the global burden of disease study. JAMA Oncol.
3:524–548. 2017. View Article : Google Scholar
|
|
3
|
DeSantis CE, Miller KD, Goding Sauer A,
Jemal A and Siegel RL: Cancer statistics for African Americans,
2019. CA Cancer J Clin. 69:211–233. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gonzalez-Angulo AM, Morales-Vasquez F and
Hortobagyi GN: Overview of resistance to systemic therapy in
patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schwartz RS and Erban JK: Timing of
metastasis in breast cancer. N Engl J Med. 376:2486–2488. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Beermann J, Piccoli MT, Viereck J and Thum
T: Non-coding RNAs in development and disease: Background,
mechanisms, and therapeutic approaches. Physiol Rev. 96:1297–1325.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yuan H, Qin Y, Zeng B, Feng Y, Li Y, Xiang
T and Ren G: Long noncoding RNA LINC01089 predicts clinical
prognosis and inhibits cell proliferation and invasion through the
Wnt/β-catenin signaling pathway in breast cancer. Onco Targets
Ther. 12:4883–4895. 2019. View Article : Google Scholar :
|
|
9
|
Hua X, Li G, Liu Z and Niu Z: LINK-A
lncRNA participates in the pathogenesis of glioma by interacting
with survivin. Exp Ther Med. 18:1581–1586. 2019.PubMed/NCBI
|
|
10
|
Liu Y, Sharma S and Watabe K: Roles of
lncRNA in breast cancer. Front Biosci (Schol Ed). 7:94–108. 2015.
View Article : Google Scholar
|
|
11
|
Li P, Zhou B, Lv Y and Qian Q: LncRNA HEIH
regulates cell proliferation and apoptosis through miR-4458/SOCS1
axis in triple-negative breast cancer. Hum Cell. 32:522–528. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang J, Li B, Wang C, Luo Y, Zhao M and
Chen P: Long non-coding RNA FOXD2-AS1 promotes glioma cell cycle
progression and proliferation through the FOXD2-AS1/miR-31/CDK1
pathway. J Cell Biochem. 120:19784–19795. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ren Z, Hu Y, Li G, Kang Y, Liu Y and Zhao
H: HIF-1α induced long noncoding RNA FOXD2-AS1 promotes the
osteosarcoma through repressing p21. Biomed Pharmacother.
117:1091042019. View Article : Google Scholar
|
|
14
|
Zhang Y, Hu J, Zhou W and Gao H: LncRNA
FOXD2-AS1 accelerates the papillary thyroid cancer progression
through regulating the miR-485-5p/KLK7 axis. J Cell Biochem. Nov
19–2018. View Article : Google Scholar : Online ahead of
print.
|
|
15
|
Jiang M, Qiu N, Xia H, Liang H, Li H and
Ao X: Long noncoding RNA FOXD2AS1/miR1505p/PFN2 axis regulates
breast cancer malignancy and tumorigenesis. Int J Oncol.
54:1043–1052. 2019.PubMed/NCBI
|
|
16
|
Tseng LM, Chiu JH, Liu CY, Tsai YF, Wang
YL, Yang CW and Shyr YM: A comparison of the molecular subtypes of
triple-negative breast cancer among non-Asian and Taiwanese women.
Breast Cancer Res Treat. 163:241–254. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
18
|
Zhou R, Xu L, Ye M, Liao M, Du H and Chen
H: Formononetin inhibits migration and invasion of MDA-MB-231 and
4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through
PI3K/AKT signaling pathways. Horm Metab Res. 46:753–760. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang X, Liu X, Luo J, Xiao W, Ye X, Chen
M, Li Y and Zhang GJ: Notch3 inhibits epithelial-mesenchymal
transition by activating Kibra-mediated Hippo/YAP signaling in
breast cancer epithelial cells. Oncogenesis. 5:e2692016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tian T, Li X, Hua Z, Ma J, Liu Z, Chen H
and Cui Z: S100A1 promotes cell proliferation and migration and is
associated with lymph node metastasis in ovarian cancer. Discov
Med. 23:235–245. 2017.PubMed/NCBI
|
|
21
|
Wang T: Association between HIF1α 1772 C/T
polymorphism and breast cancer susceptibility: A systematic review.
Crit Rev Eukaryot Gene Expr. 27:297–304. 2017. View Article : Google Scholar
|
|
22
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long noncoding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou S, Wang J and Zhang Z: An emerging
understanding of long noncoding RNAs in kidney cancer. J Cancer Res
Clin Oncol. 140:1989–1995. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang T, Huo X, Chong Z, Khan H, Liu R and
Wang T: A review of S100 protein family in lung cancer. Clin Chim
Acta. 476:54–59. 2018. View Article : Google Scholar
|
|
25
|
Grigorian M, Andresen S, Tulchinsky E,
Kriajevska M, Carlberg C, Kruse C, Cohn M, Ambartsumian N,
Christensen A, Selivanova G and Lukanidin E: Tumor suppressor p53
protein is a new target for the metastasis-associated Mts1/S100A4
protein: Functional consequences of their interaction. J Biol Chem.
276:22699–22708. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Luu HH, Zhou L, Haydon RC, Deyrup AT,
Montag AG, Huo D, Heck R, Heizmann CW, Peabody TD, Simon MA and He
TC: Increased expression of S100A6 is associated with decreased
metastasis and inhibition of cell migration and anchorage
independent growth in human osteosarcoma. Cancer Lett. 229:135–148.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Melle C, Ernst G, Schimmel B, Bleul A and
von Eggeling F: Colon-derived liver metastasis, colorectal
carcinoma, and hepatocellular carcinoma can be discriminated by the
Ca(2+)-binding proteins S100A6 and S100A11. PLoS One. 3:e37672008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
DeRycke MS, Andersen JD, Harrington KM,
Pambuccian SE, Kalloger SE, Boylan KL, Argenta PA and Skubitz AP:
S100A1 expression in ovarian and endometrial endometrioid
carcinomas is a prognostic indicator of relapse-free survival. Am J
Clin Pathol. 132:846–856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chan EH, Nousiainen M, Chalamalasetty RB,
Schafer A, Nigg EA and Sillje HH: The Ste20-like kinase Mst2
activates the human large tumor suppressor kinase Lats1. Oncogene.
24:2076–2086. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim W, Khan SK, Liu Y, Xu R, Park O, He Y,
Cha B, Gao B and Yang Y: Hepatic Hippo signaling inhibits
protumoural microenvironment to suppress hepatocellular carcinoma.
Gut. 67:1692–1703. 2018. View Article : Google Scholar
|
|
31
|
Zhou Y, Jin Q, Xiao W and Sun C:
Tankyrase1 antisense oligodeoxynucleotides suppress the
proliferation, migration and invasion through Hippo/YAP pathway in
human osteosarcoma cells. Pathol Res Pract. 215:1523812019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ehmer U and Sage J: Control of
Proliferation and Cancer Growth by the Hippo Signaling Pathway. Mol
Cancer Res. 14:127–140. 2016. View Article : Google Scholar :
|
|
33
|
Han H, Yang B, Nakaoka HJ, Yang J, Zhao Y,
Le Nguyen K, Bishara AT, Mandalia TK and Wang W: Hippo signaling
dysfunction induces cancer cell addiction to YAP. Oncogene.
37:6414–6424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yu FX, Zhang Y, Park HW, Jewell JL, Chen
Q, Deng Y, Pan D, Taylor SS, Lai ZC and Guan KL: Protein kinase A
activates the Hippo pathway to modulate cell proliferation and
differentiation. Genes Dev. 27:1223–1232. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao B, Li L, Wang L, Wang CY, Yu J and
Guan KL: Cell detachment activates the Hippo pathway via
cytoskeleton reorganization to induce anoikis. Genes Dev. 26:54–68.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Meng Z, Moroishi T, Mottier-Pavie V,
Plouffe SW, Hansen CG, Hong AW, Park HW, Mo JS, Lu W, Lu S, et al:
MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2
in the Hippo pathway. Nat Commun. 6:83572015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Guo Q, Wang J, Cao Z, Tang Y, Feng C and
Huang F: Interaction of S100A1 with LATS1 promotes cell growth
through regulation of the Hippo pathway in hepatocellular
carcinoma. Int J Oncol. 53:592–602. 2018.PubMed/NCBI
|
|
38
|
Dong H, Cao W and Xue J: Long noncoding
FOXD2-AS1 is activated by CREB1 and promotes cell proliferation and
metastasis in glioma by sponging miR-185 through targeting AKT1.
Biochem Biophys Res Commun. 508:1074–1081. 2019. View Article : Google Scholar
|
|
39
|
Liu X, Fu Q, Li S, Liang N, Li F, Li C,
Sui C, Dionigi G and Sun H: LncRNA FOXD2-AS1 functions as a
competing endogenous RNA to regulate TERT expression by sponging
miR-7-5p in thyroid cancer. Front Endocrinol (Lausanne).
10:2072019. View Article : Google Scholar
|
|
40
|
An Q, Zhou L and Xu N: Long noncoding RNA
FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer
by sponging miR-143. Biomed Pharmacother. 103:415–420. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen G, Sun W, Hua X, Zeng W and Yang L:
Long non-coding RNA FOXD2-AS1 aggravates nasopharyngeal carcinoma
carcinogenesis by modulating miR-363-5p/S100A1 pathway. Gene.
645:76–84. 2018. View Article : Google Scholar
|
